Replies to post #769973 on NorthWest Biotherapeutics Inc (NWBO)

[Investor082]

Shows how naive he is with investing, just like Zivic and ATL that he is receiving training from. His mentors predictions never come true with inflated valuations, forecasts on earnings, patient uptick, etc. Zero understanding of how biotech businesses work. However, share price always goes down when they post. Never fails!

Such a stupi* post and again confirms that LP has nothing meaningful up her sleeve post UK approval. With his prediction, LP shouldn’t be asking for an increase in authorized share count and won’t be diluting post UK approval. LP will make a fool of him, just like Senti and other minions before him!

[ROS-CH]

Far to optimistic !!!

Make no mistake : Every long invested here would love to see
and accept such developments and scenarios.

But those who are a little bit longer on this world - i.e. old farts -
know that never - NEVER EVER - everything goes as hoped for,
predicted and planned.

So I ask : What should we take out from Caravellos 'wish-list' ?

[NotSure2]

LOL, annual # of patient initialy 10 000 !!!

No way this person is a not a "fake bull", i.e a "bear in bull clothing", which post extremely ridiculous number, which turns off any new investor with common sense big time.

10 000 patient initial, LOL.

[Zadie420]

Good estimate at this time. If we include rGBM (we should) then share price will be at least 30% higher than what is mentioned in the post. Does this cover children less than 18 yrs old?

[learningcurve2020]

Oh my, the good doctor is dipping his toes into fundamentals! Bravo! Unfortunately it rarely ever works the way he’s figuring. Debt is never “fully cleared” in biotech land. IF there’s actually anything for real about DCVAX, the company will continue raising money to pursue research, other trials, and indications as it’ll take years for GBM revenue to get up to speed to actually turn a profit. At some point usually what happens is the financiers determined the stock could see more action after a reverse split with the hopes of raising more money and increasing the authorized count. Caravello also neglects to mention ( as so many do) that the company apparently in charge of all manufacturing and operations is the CEO-CFO’s private overseas CDMO. I can’t imagine that will end well for retail shareholders unless something radically changes. 🤷‍♀️

The key to great management isn’t so much the shares outstanding they’ve released but the price at which those shares were sold as the years go by.